Atrys Health (XMAD:ATRY) 3-Year RORE % : 30.64% (As of Dec. 2025)


XMAD:ATRY Atrys Health SA XMAD:ATRY
66 GF Score
Price €2.52
GF Value €3.12
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Atrys Health 3-Year RORE %?

Atrys Health XMAD:ATRY -0.40% 66 3-Year RORE % is 30.64 as of Dec. 2025. GuruFocus rates XMAD:ATRY with a GF Score™ of 66/100 and a GF Value™ of €3.12 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,294 Biotechnology companies, Atrys Health ranks better than 85.63% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Atrys Health's 3-Year RORE % for the quarter that ended in Dec. 2025 was 30.64%.

The industry rank for Atrys Health's 3-Year RORE % or its related term are showing as below:

XMAD:ATRY's 3-Year RORE % is ranked better than
85.63% of 1294 companies
in the Biotechnology industry
Industry Median: -11.54 vs XMAD:ATRY: 30.64

Atrys Health  (XMAD:ATRY) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Atrys Health 3-Year RORE % Related Terms


Atrys Health 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Atrys Health's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrys Health 3-Year RORE % Chart

Atrys Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 67.39 18.90 17.02 5.74 30.64

Atrys Health Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.02 10.08 5.74 -18.92 30.64

XMAD:ATRY vs VRTX, REGN, ALNY: 3-Year RORE % Comparison

For the Biotechnology subindustry, Atrys Health's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atrys Health 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atrys Health's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Atrys Health's 3-Year RORE % falls into.


XMAD:ATRY
66GF Score
Atrys Health SA XMAD:ATRY
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrys Health 3-Year RORE % Calculation

Atrys Health's 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -1.322--0.604 )/( -2.343-0 )
=-0.718/-2.343
=30.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 30.64 mean?
Atrys Health (XMAD:ATRY) has a 3-Year RORE % of 30.64 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Atrys Health and its competitors. According to the industry distribution chart, Atrys Health ranks #186 out of 1294 companies in the Biotechnology industry, placing it in the top 14.4%.
Is Atrys Health's 3-Year RORE % too high?
Atrys Health's current 3-Year RORE % is 30.64. Based on the distribution chart, Atrys Health ranks #186 out of 1294 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Atrys Health has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Atrys Health ranks #186 out of 1294 companies for 3-Year RORE %. This places Atrys Health in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Atrys Health and its competitors. Atrys Health's current 3-Year RORE % is 30.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.12, compared to a current price of €2.52 — trading 19.2% below its estimated fair value. The current 3-Year RORE % is 30.64. Atrys Health's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current 3-Year RORE % is 30.64 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atrys Health (XMAD:ATRY) Overvalued in 2026?

Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued. The current stock price of €2.52 is trading 19.2% below its estimated GF Value™ of €3.12. GuruFocus considers Atrys Health to be Modestly Undervalued.

Key valuation signals for XMAD:ATRY:

  • 3-Year RORE %: 30.64
  • GF Value™: €3.12 vs. price of €2.52 (19.2% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Atrys Health Business Description

Other Exchanges A2T:Germany
Address Calle Provenca, 392 planta baja, Barcelona, ESP, 08025
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
66GF Score

Get the complete analysis for XMAD:ATRY

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.52
Price
€3.12
GF Value